TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: The standard 1L therapy for PTCL that does not express CD30 is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP‐like regimen, despite minimal evidence from high-quality prospective studies.8 CHOP and CHOP-like regimens result in complete remission (CR) rates of ~65%,9,10 2-year PFS rates of 35%-47%, and 2-year OS of 53% for previously untreated PTCL.11 Although options exist for salvage therapy, responses tend to occur in a minority of patients, with reported 5-year OS of 37%.12,13